<DOC>
	<DOCNO>NCT01796717</DOCNO>
	<brief_summary>1 . To observe clinical bacteriologic response different regimen piperacillin/tazobactam ( 4.5g q6h , prolong intermittent infusion ) treatment nosocomial pneumonia . 2 . To describe pharmacokinetic profile piperacillin/tazobactam ( 4.5g q6h , prolong intermittent infusion ) patient nosocomial pneumonia . 3 . To assess safety profile piperacillin/tazobactam 4.5g q6h , prolong intermittent infusion patient nosocomial pneumonia .</brief_summary>
	<brief_title>Optimizing Dosing Regimen Piperacillin/Tazobactam Nosocomial Pneumonia</brief_title>
	<detailed_description>Enrolled patient randomize therapeutic control group . Controlled group receive piperacillin/tazobactam 4.5g Q6h , intermittent infusion 30 minute . Therapy group receive piperacillin/tazobactam 4.5g Q6h , prolong infusion 4 hour . The duration 7-14 day . Two set blood culture ( aerobic anaerobic culture ) obtain study post-treatment period first blood culture positive . Cultures low respiratory tract infection obtain ( within 48 h ) study last day therapy . The low respiratory tract specimen obtain either endotracheal aspiration , bronchoalveolar lavage ( BAL ) , protect brush procedure ( PBP ) sputum require show &gt; 25 polymorphonuclear cell &lt; 10 squamous epithelial cell per field ( 100× magnification ) . The plasma concentration piperacillin tazobactam determine LC/MS/MS method . The QC sample also analyze simultaneously run method stability testing , accord laboratory standard procedure .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>1 . Male female , age 18 70 year old . 2 . Inpatients nosocomial pneumonia bacteremia . . Diagnosis nosocomial pneumonia 1 . Chest radiographic infiltrate new progressive . 2 . At least two follow clinical finding suggest infection . New onset fever , oral temperature T &gt; 38.3℃ T &lt; 36℃ Purulent sputum WBC &gt; 12×10^9/L &lt; 4×10^9/L , band form &gt; 10 % PaO2/FIO2 &lt; 240mmHg ii . Diagnosis bacteremia : Positive blood culture isolate bacterial strain consider infection cause . 3 . Patients infect piperacillintazobactam susceptible pathogen MIC=4 , 8 16mg/L . 1 . The patient receive systematic antibacterial treatment 48 hour enrollment clinical response . 2 . Severe pyemia hypotension or/and evidence failure organic function ( shock : systolic pressure &lt; 90mmHg diastolic pressure &lt; 60mmHg , require 4 hour administration vasopressor ( ) ；renal impairment : urine volume &lt; 20 ml∕h &lt; 80 ml∕4h exclude potential , acute renal failure need dialysis , CLcr &lt; 40 mL/min ) . 3 . Documented infection cause pathogen beyond antibacterial spectrum piperacillin/tazobactam . 4 . Previously diagnose condition tend mimic complicate course evaluation infectious process , e.g . bronchial obstruction , obstructive pneumonia , activate pulmonary malignancy , pulmonary abscess , empyema active tuberculosis , might interfere course infectious disease evaluation disease . 5 . History allergy penicillin . 6 . Pregnancy breastfeed woman . 7 . Any condition investigator consider might increase risk patient interfere study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Piperacillin/tazobactam</keyword>
	<keyword>MIC</keyword>
</DOC>